Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 4/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
| ▸ | FFAR3 | O14843 | 3/20 | 0.35 |
| ▸ | CTSD | P07339 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3112427 | 1.00 | HDAC3 (0.41) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL11567005 | 0.83 | TDP1 (0.45) | TDP1ALDH1A1FFAR3 | |
| SCHEMBL21192575 | 0.77 | HDAC3 (0.37) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL21192574 | 0.77 | HDAC3 (0.37) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL640375 | 0.75 | — | — | |
| SCHEMBL9005200 | 0.75 | — | — | |
| SCHEMBL640374 | 0.75 | — | — | |
| SCHEMBL758250 | 0.74 | — | — | |
| SCHEMBL31302963 | 0.74 | CES2 (0.48) | TDP1ALDH1A1CES2CES1TSHR | |
| SCHEMBL9210840 | 0.72 | GAA (0.54) | HDAC3HDAC1HDAC2HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2257284-A2 | METHODS OF TREATING SKIN WITH AROMATIC SKIN-ACTIVE INGREDIENTS | MARY KAY INC. (US) | 2010-12-08 | — | — | EP | claimed |
| WO-2009099890-A2 | METHODS OF TREATING SKIN WITH AROMATIC SKIN-ACTIVE INGREDIENTS | MARY KAY INC. (US) | 2009-08-13 | — | — | WO | claimed |
| US-20090197939-A1 | METHODS OF TREATING SKIN WITH AROMATIC SKIN-ACTIVE INGREDIENTS | MARY KAY INC. (US) | 2009-08-06 | — | — | US | claimed |
| US-12280017-B2 | Methods of treating skin with aromatic skin-active ingredients | MARY KAY INC. (US) | 2025-04-22 | — | — | US | disclosed |
| US-20190314295-A1 | METHODS OF TREATING SKIN WITH AROMATIC SKIN-ACTIVE INGREDIENTS | MARY KAY INC. | 2019-10-17 | — | — | US | disclosed |
| US-8399521-B2 | Methods of treating skin with aromatic skin-active ingredients | MARY KAY INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-20100249222-A1 | METHODS OF TREATING SKIN WITH AROMATIC SKIN-ACTIVE INGREDIENTS | MARY KAY INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20090197939-A1 | METHODS OF TREATING SKIN WITH AROMATIC SKIN-ACTIVE INGREDIENTS | MARY KAY INC. (US) | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197939-A1 | METHODS OF TREATING SKIN WITH AROMATIC SKIN-ACTIVE INGREDIENTS | MMP8, LOX, TYR | HDAC3 1946/4885HDAC1 963/4885HDAC2 1154/4885 |
| US-12280017-B2 | Methods of treating skin with aromatic skin-active ingredients | MMP9, MMP1, MMP17 | HDAC3 463/4885HDAC1 276/4885HDAC2 481/4885 |
| US-20190314295-A1 | METHODS OF TREATING SKIN WITH AROMATIC SKIN-ACTIVE INGREDIENTS | MMP9, MMP1, MMP17 | HDAC3 463/4885HDAC1 276/4885HDAC2 481/4885 |
| US-20100249222-A1 | METHODS OF TREATING SKIN WITH AROMATIC SKIN-ACTIVE INGREDIENTS | MMP8, LOX, TYR | HDAC3 1946/4885HDAC1 963/4885HDAC2 1154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.